Emily K. Curran, MD, discusses how newer ALL therapies are reshaping treatment decisions and minimal residual disease monitoring for older adults.
Emily K. Curran, MD
Advertisement
Articles by Emily K. Curran, MD
Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.
Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
5